Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

OXiGENE Inc (NASDAQ:OXGN)

1.19
Delayed Data
As of Aug 31
 +0.01 / +0.85%
Today’s Change
1.01
Today|||52-Week Range
2.53
-26.09%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$31.3M

Company Description

Oxigene, Inc. engages in the development of therapeutics to treat cancer and eye diseases. The company is a clinical-stage, biopharmaceutical company developing novel therapeutics primarily to treat cancer. It offers anti-vascular drugs referred to as vascular disrupting agents. The company was founded in 1988 and is headquartered in South San Francisco, CA.

Contact Information

Oxigene, Inc.
701 Gateway Boulevard
South San Francisco California 94080
P:(650) 635-7000
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

William D. SchwietermanPresident, Chief Executive Officer & Director
Matthew M. LoarChief Financial & Accounting Officer
Jai BalkissoonVice President-Clinical Development
David J. ChaplinChief Scientific Officer & Director
Kathleen M. LeeVice President-Chemistry, Manufacturing & Controls